These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

343 related items for PubMed ID: 31790499

  • 1. Expression of myeloid Src-family kinases is associated with poor prognosis in AML and influences Flt3-ITD kinase inhibitor acquired resistance.
    Patel RK, Weir MC, Shen K, Snyder D, Cooper VS, Smithgall TE.
    PLoS One; 2019; 14(12):e0225887. PubMed ID: 31790499
    [Abstract] [Full Text] [Related]

  • 2. A dual inhibitor overcomes drug-resistant FLT3-ITD acute myeloid leukemia.
    Wang P, Xiao X, Zhang Y, Zhang B, Li D, Liu M, Xie X, Liu C, Liu P, Ren R.
    J Hematol Oncol; 2021 Jul 03; 14(1):105. PubMed ID: 34217323
    [Abstract] [Full Text] [Related]

  • 3. Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells.
    Stölzel F, Steudel C, Oelschlägel U, Mohr B, Koch S, Ehninger G, Thiede C.
    Ann Hematol; 2010 Jul 03; 89(7):653-62. PubMed ID: 20119833
    [Abstract] [Full Text] [Related]

  • 4. Ningetinib, a novel FLT3 inhibitor, overcomes secondary drug resistance in acute myeloid leukemia.
    Hu C, Zhang Y, Yang J, Xu Y, Deng T, Li Y, Xu S, Wang S, Wang P.
    Cell Commun Signal; 2024 Jul 08; 22(1):355. PubMed ID: 38978049
    [Abstract] [Full Text] [Related]

  • 5. Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth.
    Weir MC, Hellwig S, Tan L, Liu Y, Gray NS, Smithgall TE.
    PLoS One; 2017 Jul 08; 12(7):e0181178. PubMed ID: 28727840
    [Abstract] [Full Text] [Related]

  • 6. Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns.
    Moore AS, Faisal A, Gonzalez de Castro D, Bavetsias V, Sun C, Atrash B, Valenti M, de Haven Brandon A, Avery S, Mair D, Mirabella F, Swansbury J, Pearson AD, Workman P, Blagg J, Raynaud FI, Eccles SA, Linardopoulos S.
    Leukemia; 2012 Jul 08; 26(7):1462-70. PubMed ID: 22354205
    [Abstract] [Full Text] [Related]

  • 7. An essential pathway links FLT3-ITD, HCK and CDK6 in acute myeloid leukemia.
    Lopez S, Voisset E, Tisserand JC, Mosca C, Prebet T, Santamaria D, Dubreuil P, De Sepulveda P.
    Oncotarget; 2016 Aug 09; 7(32):51163-51173. PubMed ID: 27323399
    [Abstract] [Full Text] [Related]

  • 8. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.
    Zhang W, Gao C, Konopleva M, Chen Y, Jacamo RO, Borthakur G, Cortes JE, Ravandi F, Ramachandran A, Andreeff M.
    Clin Cancer Res; 2014 May 01; 20(9):2363-74. PubMed ID: 24619500
    [Abstract] [Full Text] [Related]

  • 9. Amino alkynylisoquinoline and alkynylnaphthyridine compounds potently inhibit acute myeloid leukemia proliferation in mice.
    Naganna N, Opoku-Temeng C, Choi EY, Larocque E, Chang ET, Carter-Cooper BA, Wang M, Torregrosa-Allen SE, Elzey BD, Lapidus RG, Sintim HO.
    EBioMedicine; 2019 Feb 01; 40():231-239. PubMed ID: 30686755
    [Abstract] [Full Text] [Related]

  • 10. LT-171-861, a novel FLT3 inhibitor, shows excellent preclinical efficacy for the treatment of FLT3 mutant acute myeloid leukemia.
    Yu Z, Du J, Hui H, Kan S, Huo T, Zhao K, Wu T, Guo Q, Lu N.
    Theranostics; 2021 Feb 01; 11(1):93-106. PubMed ID: 33391463
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target.
    Park IK, Mishra A, Chandler J, Whitman SP, Marcucci G, Caligiuri MA.
    Blood; 2013 Mar 14; 121(11):2064-73. PubMed ID: 23321254
    [Abstract] [Full Text] [Related]

  • 12. Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.
    Kancha RK, Grundler R, Peschel C, Duyster J.
    Exp Hematol; 2007 Oct 14; 35(10):1522-6. PubMed ID: 17889720
    [Abstract] [Full Text] [Related]

  • 13. LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML.
    Beeharry N, Landrette S, Gayle S, Hernandez M, Grotzke JE, Young PR, Beckett P, Zhang X, Carter BZ, Andreeff M, Halene S, Xu T, Rothberg J, Lichenstein H.
    Blood Adv; 2019 Nov 26; 3(22):3661-3673. PubMed ID: 31751472
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia.
    Lee-Sherick AB, Zhang W, Menachof KK, Hill AA, Rinella S, Kirkpatrick G, Page LS, Stashko MA, Jordan CT, Wei Q, Liu J, Zhang D, DeRyckere D, Wang X, Frye S, Earp HS, Graham DK.
    Oncotarget; 2015 Mar 30; 6(9):6722-36. PubMed ID: 25762638
    [Abstract] [Full Text] [Related]

  • 15. Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML.
    Jeon JY, Zhao Q, Buelow DR, Phelps M, Walker AR, Mims AS, Vasu S, Behbehani G, Blachly J, Blum W, Klisovic RB, Byrd JC, Garzon R, Baker SD, Bhatnagar B.
    Invest New Drugs; 2020 Apr 30; 38(2):340-349. PubMed ID: 31102119
    [Abstract] [Full Text] [Related]

  • 16. Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib via STAT5-and hypoxia-dependent upregulation of AXL.
    Dumas PY, Naudin C, Martin-Lannerée S, Izac B, Casetti L, Mansier O, Rousseau B, Artus A, Dufossée M, Giese A, Dubus P, Pigneux A, Praloran V, Bidet A, Villacreces A, Guitart A, Milpied N, Kosmider O, Vigon I, Desplat V, Dusanter-Fourt I, Pasquet JM.
    Haematologica; 2019 Oct 30; 104(10):2017-2027. PubMed ID: 30923103
    [Abstract] [Full Text] [Related]

  • 17. Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia.
    Park IK, Mundy-Bosse B, Whitman SP, Zhang X, Warner SL, Bearss DJ, Blum W, Marcucci G, Caligiuri MA.
    Leukemia; 2015 Dec 30; 29(12):2382-9. PubMed ID: 26172401
    [Abstract] [Full Text] [Related]

  • 18. Metformin synergizes with gilteritinib in treating FLT3-mutated leukemia via targeting PLK1 signaling.
    Chen M, Shen C, Chen Y, Chen Z, Zhou K, Chen Y, Li W, Zeng C, Qing Y, Wu D, Xu C, Tang T, Che Y, Qin X, Xu Z, Wang K, Leung K, Sau L, Deng X, Hu J, Wu Y, Chen J.
    Cell Rep Med; 2024 Jul 16; 5(7):101645. PubMed ID: 39019012
    [Abstract] [Full Text] [Related]

  • 19. N-(3-Methoxyphenyl)-6-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl)pyridin-2-amine is an inhibitor of the FLT3-ITD and BCR-ABL pathways, and potently inhibits FLT3-ITD/D835Y and FLT3-ITD/F691L secondary mutants.
    Wang X, DeFilippis RA, Leung YK, Shah NP, Li HY.
    Bioorg Chem; 2024 Feb 16; 143():106966. PubMed ID: 37995643
    [Abstract] [Full Text] [Related]

  • 20. A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations.
    Yamaura T, Nakatani T, Uda K, Ogura H, Shin W, Kurokawa N, Saito K, Fujikawa N, Date T, Takasaki M, Terada D, Hirai A, Akashi A, Chen F, Adachi Y, Ishikawa Y, Hayakawa F, Hagiwara S, Naoe T, Kiyoi H.
    Blood; 2018 Jan 25; 131(4):426-438. PubMed ID: 29187377
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.